文献速递消化系统肿瘤

PEG修饰IL-10联合FOLFOX二线治疗吉西他滨难治性转移性胰腺癌的随机III期研究

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
PubMed 文献 · J Clin Oncol · 2021-02-08

SEQUOIA研究比较PEG化重组人IL-10(pegilodecakin)联合FOLFOX与单用FOLFOX在吉西他滨治疗进展后的转移性胰腺导管腺癌患者中的疗效与安全性。共随机567例患者,主要终点总生存期在两组间相似(中位5.8 vs 6.3个月,HR=1.045,95%CI 0.863-1.265),联合组未改善疗效,安全性可控。

要点

  • PEG联合FOLFOX未改善吉西他滨难治性转移性胰腺癌的总生存期。
  • 联合组血小板减少(55% vs 20%)和贫血(40% vs 16%)发生率更高。
  • 探索性分析显示PEG增加IL-18、IFN-γ和颗粒酶B,降低TGF-β。

核心结论

  • 在吉西他滨难治性转移性胰腺导管腺癌患者中,PEG联合FOLFOX相比单用FOLFOX未改善疗效。
  • 安全性结果与既往PEG联合化疗观察一致,毒性可管理且可耐受。

研究设计与样本

  • SEQUOIA是一项全球随机III期研究,比较PEG+FOLFOX与FOLFOX二线治疗吉西他滨难治性胰腺导管腺癌。
  • 2017年3月1日至2019年9月9日共随机567例患者,PEG+FOLFOX组283例,FOLFOX组284例,按既往吉西他滨用药和地区分层。
  • 合格患者仅接受过一种含吉西他滨的治疗,主要终点为总生存期。

主要发现

  • PEG+FOLFOX组与FOLFOX组中位总生存期分别为5.8个月和6.3个月(HR=1.045,95%CI 0.863-1.265)。
  • 中位无进展生存期两组均为2.1个月(HR=0.981,95%CI 0.808-1.190)。
  • 客观缓解率分别为4.6%和5.6%。
  • PEG+FOLFOX组与FOLFOX组常见(≥35%)治疗中出现的不良事件包括血小板减少(55% vs 20%)、贫血(40% vs 16%)、乏力(61% vs 45%)、中性粒细胞减少(39% vs 28%)、腹痛(37% vs 29%)、恶心(45% vs 41%)、神经病变(37% vs 38%)和食欲下降(35% vs 31%)。
  • 探索性分析显示加用PEG后总IL-18、干扰素-γ和颗粒酶B增加,转化生长因子-β降低。

临床怎么用

  • 不推荐在吉西他滨难治性转移性胰腺癌二线治疗中常规加用pegilodecakin联合FOLFOX。
  • 联合PEG时需关注血小板减少和贫血等血液学毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following progression on first-line gemcitabine-containing therapy with metastatic pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: SEQUOIA, a randomized, global phase III study, compared FOLFOX with PEG + FOLFOX as second line in gemcitabine-refractory PDAC. Patients were randomly assigned 1:1 (PEG + FOLFOX:FOLFOX) and stratified by prior gemcitabine and region. Eligible patients had only one prior gemcitabine-containing treatment. Primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), response evaluation per Response Evaluation Criteria in Solid Tumor (RECIST) 1.1, and safety. Exploratory analyses included biomarkers related to immune activation. RESULTS: Between March 1, 2017, and September 9, 2019, 567 patients were randomly assigned PEG + FOLFOX (n = 283) or FOLFOX (n = 284). Most (94.7%) patients received prior gemcitabine plus nab paclitaxel. OS was similar comparing PEG + FOLFOX versus FOLFOX (median: 5.8 v 6.3 months; hazard ratio = 1.045; 95% CI, 0.863 to 1.265). Also, PFS (median 2.1 v 2.1 months; hazard ratio = 0.981; 95% CI, 0.808 to 1.190) and objective response rate (4.6% v 5.6%) were similar between the treatment arms. Most common (≥ 35%) treatment-emergent adverse events in PEG + FOLFOX versus FOLFOX were thrombocytopenia (55% v 20%), anemia (40% v 16%), fatigue (61% v 45%), neutropenia (39% v 28%), abdominal pain (37% v 29%), nausea (45% v 41%), neuropathy (37% v 38%), and decreased appetite (35% v 31%). Exploratory analyses revealed increases in total IL-18, interferon (IFN)-γ, and granzyme B and decreases in transforming growth factor (TGF)-β with the addition of PEG. CONCLUSION: PEG added to FOLFOX did not improve efficacy in advanced gemcitabine-refractory PDAC. Safety findings were consistent as previously observed from PEG with chemotherapy; toxicity was manageable and tolerable. Exploratory pharmacodynamic results were consistent with immunostimulatory signals of the IL-10R pathway.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hecht JR, Lonardi S, Bendell J, et al. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). J Clin Oncol. 2021. PMID: 33555926. doi:10.1200/JCO.20.02232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。